Understanding PGx Results Interpretation

Interpreting PGx Results in Clinical Practice

We often hear from GPs and prescribers that the challenge with pharmacogenomics isn’t the science itself, but interpreting the results with confidence. In particular, clinicians want clearer, practical guidance on PGx phenotypes and what labels such as poor, intermediate, or ultra-rapid metaboliser actually mean for real-world prescribing decisions.

This webinar is designed to address that gap. You’ll learn how to interpret common PGx metaboliser types, understand how phenotypes influence drug exposure and response, and apply these insights across frequently prescribed medicines including antidepressants, pain medications, statins, and other long-term therapies.

Using real PGx report examples, we’ll walk through how to translate genetic results into safe, effective prescribing choices. As primary care increasingly manages complex cases involving mental health, chronic pain, and polypharmacy—and with NHS interest in personalised prescribing continuing to grow—this session aims to build practical confidence in using PGx as part of everyday clinical decision-making.